Clinical Trials Browser

Interventional × HER2-negative Breast Cancer × camrelizumab × Clear all

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Phase 2 Unknown

HER2-negative Breast Cancer